Simultaneous targeted activation of Notch1 and Vhl-disruption in the kidney proximal epithelial tubular cells in mice

Johansson, Elinn; Rönö, Birgitte; Johansson, Martin; Lindgren, David; Möller, Christina; Axelson, Håkan; Smith, Emma M. K.

doi:10.1038/srep30739

Download PDF

Article
Open access
Published: 05 August 2016

Simultaneous targeted activation of Notch1 and Vhl-disruption in the kidney proximal epithelial tubular cells in mice

Elinn Johansson¹,
Birgitte Rönö¹^nAff3,
Martin Johansson²,
David Lindgren¹,
Christina Möller¹,
Håkan Axelson¹^na1 &
…
Emma M. K. Smith¹^na1

Scientific Reports volume 6, Article number: 30739 (2016) Cite this article

2110 Accesses
7 Citations
Metrics details

Subjects

Abstract

Clear cell renal cell carcinoma (ccRCC) is the most common subtype of kidney cancer, representing approximately 75% of all renal neoplasms. ccRCC is known to be strongly associated with silencing of the von Hippel Lindau (VHL) tumor suppressor gene, yet VHL deficiency alone does not seem to be sufficient to drive the oncogenic transformation of normal renal epithelium and induce renal tumorigenesis. We, and others, have previously suggested that constitutive activation of the Notch signaling pathway, alongside with VHL loss, contribute to the oncogenic features of ccRCC. Here we report a prevailing hyperactivation of the Notch1 receptor in human ccRCC relative to the healthy counterpart. To explore the consequences of the elevated Notch1 signaling observed in ccRCC patient material, we made use of a conditional mouse model based on concurrent ectopic expression of constitutively active Notch1 (NICD1) and deletion of the Vhl gene. Histological examination of the kidneys of the conditional mice demonstrate the existence of nests of dysplastic cells with a clear cytoplasm as a consequence of lipid accumulation, thus displaying a one important hallmark of human ccRCC.

Novel genetically engineered mouse models for clear cell renal cell carcinoma

Article Open access 22 May 2023

Mechanism of cystogenesis by Cd79a-driven, conditional mTOR activation in developing mouse nephrons

Article Open access 10 January 2023

HIF-1α and HIF-2α differently regulate tumour development and inflammation of clear cell renal cell carcinoma in mice

Article Open access 17 August 2020

Introduction

Renal cancers comprise a diverse group of solid tumors that account for approximately 3% of all new cancer cases each year¹. Clear cell renal cell carcinoma (ccRCC) is by far the most common renal neoplasm representing about 75% of all cases^2,3. Several lines of evidence indicate that ccRCC tumors originate from the proximal tubular compartment^4,5. Histologically, ccRCC is characterized by solid nests of tumor cells with a clear cytoplasm, which is due to an abnormal cytoplasmatic accumulation of cholesterol, cholesterol esters, other neutral lipids and glycogen^6,7. The vast majority of sporadic ccRCCs are associated with somatic biallelic inactivation of the tumor suppressor gene von Hippel-Lindau (VHL) and the consequent stabilization of hypoxia-inducible factor (HIF) α subunits, and hence a constitutively activated hypoxic response^8,9,10. Although the absence of functional VHL protein (pVHL) and the resulting accumulation of HIF-α is crucial to ccRCC pathogenesis^11,12,13, kidney-restricted ablation of Vhl in transgenic mice has repeatedly been shown to be insufficient to induce renal tumorigenesis^14,15,16,17. Moreover, germline inactivation of the VHL gene, associated with the von Hippel-Lindau syndrome, is accompanied by a high frequency of renal cysts, which only occasionally develop into ccRCC¹⁸. Taken together, these observations strongly indicate that in addition to VHL-inactivation, there is a requirement for additional genetic alterations to provoke ccRCC tumor development. This statement was further supported by recent major sequencing efforts that indicate that chromatin modifying genes often are mutated in ccRCC in conjunction with loss of pVHL, thus representing a major cooperating pathway^19,20,21.

Notch signaling is an evolutionary conserved pathway of great importance both during embryonic development and postnatal life. Aberrant Notch signaling has been associated with multiple human disorders, particularly a wide range of cancers in which Notch, depending on the affected tissue and cell type, act as a tumor suppressor or, when overactive, a potent oncogene²². The oncogenic role of Notch was first established in 1991 in T-cell acute lymphoblastic leukemia (T-ALL)²³, and has since then gradually expanded to include also breast cancer^24,25, lung adenocarcinoma^26,27, melanoma²⁸, and glioma²⁹ to name a few. The consequences of Notch-driven tumorigenesis can partly be explained by the function of direct target genes as inducers of proliferation and tumor-cell survival³⁰. Recent evidence has suggested that Notch signaling also regulates self-renewal and survival of cancer stem cells (CSCs)^31,32, participates in epithelial-mesenchymal transition (EMT)³³, increases therapy resistance^34,35,36, triggers a metabolic switch towards aerobic glycolysis, also known as the Warburg effect³⁷, and affects tumor angiogenesis^38,39.

During the past years Notch has emerged as a potential oncogene also in renal neoplasms; several research groups have concluded that high expression of the Notch ligands Jagged1 and Delta-like4 correlates with an increased risk of distant metastasis and worse prognosis in patients with ccRCC^40,41,42.

Moreover, we have previously shown that the expression level of the Notch1 receptor is significantly increased in ccRCC cells compared with the adjacent non-neoplastic renal tissue, and that blocking of Notch1 attenuates the proliferative growth of ccRCC cell lines and primary cultures in vitro and in a xenograft model in vivo⁴³. Notch signaling has also been reported to stimulate the invasive and migratory capacity of ccRCC cells^41,44,45,46 and to have a direct role in the development of EMT in cultured human primary proximal epithelial cells⁴⁷.

To determine whether Notch signaling could induce an oncogenic switch in renal proximal tubular epithelial cells (PTECs) in vivo, we used a conditional mouse model based on the ectopic expression of constitutively active intracellular domain of Notch1 (NICD1) and the disruption of the Vhl-gene. These mice did not develop any apparent renal disorder during the time course of this study. However, immunohistological analysis of the kidneys of the conditional mice revealed nests of dysplatic cells with a clear cytoplasm as a consequence of lipid accumulation, thus reproducing the key feature of early human ccRCC carcinogenesis.

Results

Increased activity of Notch1 signaling in ccRCC

We have previously reported that the Notch1 receptor is upregulated in human ccRCC compared to healthy renal epithelial cells⁴³. To examine whether Notch1 activity, i.e. signaling through the Notch1 receptor, also was elevated in ccRCC, we stained a tissue micro array (TMA) with 56 ccRCC samples and 4 samples with normal renal tissue, using an antibody raised against the intracellular part of cleaved human Notch1 (NICD1) (Fig. 1A–C). We found positive staining in 53 out of 56 tumors, whereas the normal renal tissue showed no NICD1 staining (Fig. 1A). It was also clear that the activation of Notch1 was restricted to the tumor compartment as the surrounding stromal tissue stained negatively for NICD1 (Fig. 1C, arrow). Furthermore, analyzes of the TCGA data set comprising 527 ccRCC and 128 normal kidney cortical samples revealed elevated expression of Notch1 and the Notch target genes Hey1 and Hey2 in ccRCC in comparison to the normal samples (Fig. 1D,E). These results corroborate previous reports showing that elevated Notch1 signaling is common feature of human ccRCC^43,44,48.

The ectopic expression of NICD1 and silencing of Vhl is restricted to the PTECs in androgen treated Vhl^fl/fl/CALSL-NICD/Kap2-iCre transgenic mice

Currently, existing data supports a role for Notch1 in the tumorigenic process of ccRCC^{43,45,48,49,50}. To test whether Notch1 signaling act as a key factor in ccRCC-development in vivo, we crossed the transgenic mouse line CALSL-NICD that conditionally confers ectopic expression of human NICD1⁵¹, with mice carrying a floxed Vhl (Vhl^fl/fl) allele⁵², and the Kap2-iCre mouse strain⁵³, in which improved Cre (iCre) is driven by the androgen inducible and PTEC specific kidney androgen protein 2 (Kap2) promoter (Fig. 2A). Our choice of Cre-driver in this system was based on recent data that reinforces the notion that ccRCC originates from the proximal compartment of the nephron^4,5, and the fact that VHL loss in conjunction with development of sporadic ccRCC most probably occurs in fully differentiated adult proximal tubular cells. To assure that the Kap2-promoter is androgen inducible, and its activity is limited to the renal PTECs, we crossed the Kap2-iCre transgenic mouse with an R26R-YFP reporter mouse. Upon immunohistological analysis of the R26R-YFP/Kap2-iCre mice, focal YFP expression was detected in a subset of tubules in the renal cortex of the androgen treated R26R-YFP/Kap2-iCre animals but not in the control group (Fig. 2B).

Next, we wanted to verify adequate Kap2-iCre controlled activation/excision of the CALSL-NICD and Vhl^fl/fl transgenes. For this purpose, we quantified the expression levels of Notch1 and the Notch target gene Hey1 in renal cortex of Vhl^fl/fl/CALSL-NICD/Kap2-iCre by qPCR. As expected, androgen treatment significantly enhanced the expression of Notch1 and Hey1 in Vhl^fl/fl/CALSL-NICD/Kap2-iCre mice compared to control (Fig. 2C).

Carbonic anhydrase IX (CAIX) is a well-accepted surrogate marker of hypoxia that is known to be up-regulated upon loss of Vhl⁵⁴. In accordance with this, CAIX staining was detected at similar levels in the kidney cortex of androgen treated Vhl^fl/fl/CALSL-NICD/Kap2-iCre and Vhl^fl/fl/Kap2-iCre mice, but not in control mice (Fig. 2D–F). Immunofluorescent co-staining of CAIX and the PTEC marker Lotus tetragonolobus agglutinin (LTA) confirmed that the Vhl was deleted specifically in the proximal tubules (Fig. 3G). Taken together, these results indicate that the Kap2-iCre transgene admits to efficient Cre-mediated recombination of the CALSL-NICD and Vhl^fl/fl transgenes in an androgen dependent and PTEC-restricted manner.

**Figure 3: Ectopic activation of NICD1 is associated with the appearance of cells with a clear cytoplasm in the renal cortex.**

Ectopic expression of constitutively active Notch1 drives the formation of dysplastic PTECs with a clear cytoplasm

To evaluate the consequences of ectopic expression of NICD1 and/or the loss of Vhl in the PTECs, Vhl^fl/fl/CALSL-NICD/Kap2-iCre and Vhl^fl/fl/Kap2-iCre were sacrificed 12 months after receiving a subcutaneous implant of a 10 mg, thirty-day release testosterone pellet.

The androgen treated animals appeared healthy all through the experiment, and no prominent difference in the renal gross morphology between androgen treated animals and the respective control group, or between androgen induced Vhl^fl/fl/CALSL-NICD/Kap2-iCre and Vhl^fl/fl/Kap2-iCre mice, was noted at the time of analysis. To asses differences at the molecular level; we first stained formalin fixed paraffin embedded (FFPE) kidneys from androgen treated Vhl^fl/fl/CALSL-NICD/Kap2-iCre, Vhl^fl/fl/Kap2-iCre and Vhl^fl/fl/CALSL-NICD mice with the proliferation marker ki67. In this mouse model we noticed no difference in tubular or interstitial proliferation index as shown by ki67 staining (Figure S1A). It has been reported that Vhl deletion might lead to increased renal fibrosis⁵⁵. To investigate if this was the case also in our model, we stained the kidney tissue from the androgen induced Vhl^fl/fl/CALSL-NICD/Kap2-iCre, Vhl^fl/fl/Kap2-iCre and Vhl^fl/fl/CALSL-NICD mice with Masson’s Trichrome histochemical stain, in order to assess changes in the extent of kidney fibrosis. However, we noted no significant increase in the degree of interstitial or tubular fibrosis, indicating that fibrosis is not affected in our model system (Figure S1B). Further, podocalyxin staining showed that silencing of Vhl and ectopic expression of NICD1 did not confer any changes in the renal vascular structure (Figure S1C).

With regards to malignant growth, we found a lesion in one of the androgen induced Vhl^fl/fl/CALSL-NICD/Kap2-iCre mice (n = 12) (Fig. 3). Histologically it consisted of a thin surrounding pseudocapsule covering a tumor displaying a papillary and cribriform growth pattern. The tumor cells showed distinct nuclear pleomorphismhad and slightly enlarged nuclei. To verify that this adenoma was indeed associated with Vhl deletion, we stained consecutive sections of the lesion with antibodies directed against acknowledged HIF target proteins as CAIX (Fig. 3, middle) and Glut-1 (Fig. 3, right). These markers are also used clinically as histopathological markers for ccRCC. The tumor stained positively for both markers indicating that this lesion displayed the characteristics of Vhl deletion.

Surprisingly, upon H&E staining of androgen treated Vhl^fl/fl/CALSL-NICD/Kap2-iCre mice frequently displayed nests of dysplastic cells with a clear cytoplasm (Fig. 3B,C). Quantification of the number of areas with clear cells per area, demonstrates that the number of these cells was significantly increased in the androgen treated Vhl^fl/fl/CALSL-NICD/Kap2-iCre mice compared to the androgen treated Vhl^fl/fl/Kap2-iCre mice (Fig. 3D). H&E and CAIX staining on consecutive sections from Vhl^fl/fl/CALSL-NICD/Kap2-iCre mice showed co-concordance of the clear cell phenotype with markers for Vhl loss (Fig. 4E). Together, this data suggest that the clear cell phenotype is induced by the activation of NICD1 in the context of Vhl deletion.

**Figure 4: The clear cell phenotype is linked to the accumulation of cytoplasmic lipids.**

The Notch signaling pathway plays a role in renal lipidogenesis

As the clear cell morphology is hallmark of ccRCC, we wanted to further analyze the cellular content of the clear cells observed in the androgen treated Vhl^fl/fl/CALSL-NICD/Kap2-iCre mice. We could however not detect any increase in staining with Periodic acid-Schiff (PAS) in the clear cell nodules, indicating that the clear cell morphology was not a consequence of increased deposition of glycogen (Fig. 4A).

Next, we performed Oil red O (ORO) staining to assess accumulation of triglycerides and other neutral lipids. Interestingly, ORO staining was only detected in the androgen treated Vhl^fl/fl/CALSL-NICD/Kap2-iCre mice, but not in the androgen treated Vhl^fl/fl/Kap2-iCre mice (Fig. 4B). It should be noted that the ORO stainings were performed using cryopreserved tissue, which explains the lack of cytoplasmic clearing associated with FFPE tissue processing. These results suggest that activation of Notch plays a role in the lipid accumulation process that occurs in the VHL negative proximal tubular cells during ccRCC progression.

To further substantiate a role for Notch signaling in accumulation of lipids in ccRCC cells, we performed in vitro experiments using an established ccRCC cell line 786-O. 786-O cells, like virtually all established ccRCC cell lines, display a sarcomatoid morphology during conventional in vitro growth. We therefore employed a protocol established for in vitro differentiation of fibroblasts to adipocytes. 786-O cells displayed a modest positive staining with ORO when grown in conventional growth medium. After two weeks of treatment with the adipocyte differentiation medium a strong enhancement of ORO staining was detected (Fig. 4C). To assess the contribution of Notch signaling to the accumulation of lipids we treated the cells with DAPT, an inhibitor of the gamma-secretase activity that is required for activation of endogenous Notch signaling. A pronounced inhibition of the induced lipid accumulation was noted. Together these results suggest that enhanced Notch signaling in the context of ccRCC might contribute the characteristic cytoplasmic lipid accumulation, which is a hallmark of this tumor type.

Discussion

ccRCC is the most common form of kidney cancer. Worldwide, approximately 270 000 new cases are diagnosed each year, and about 116 000 patients die of the complications of this disease⁵⁶. Metastatic ccRCC is known to be extremely resistant to conventional cancer treatments and the outcome is poor with a median survival of less than one year. For this reason, the development of new therapies that act upon specific abnormalities in ccRCC is highly motivated. In this regard, a mouse model that reflects human ccRCC would offer an excellent opportunity to study and manipulate ccRCC growth mechanisms in a genetically defined setting in the context of ccRCC tumor microenvironment. As loss of VHL is so strongly associated with initiation of ccRCC, several efforts have been made to target this tumor suppressor gene in mice. So far, all attempts to generate a ccRCC mouse model that phenocopies the hallmarks of ccRCC, i.e. the clear cell histology associated with perturbed metabolic control in combination with metastatic potential has proven difficult; Mice homozygous for the Vhl null allele die in utero because of vascular abnormalities of the placenta⁵⁷, while Vhl^+/− mice⁵² or mice in which Vhl was mosaically deleted with a human β-actin driven Cre⁵⁸, did not display any signs of renal pathology. Similarly, conditional inactivation of Vhl in the distal tubule and ascending loop of Henle failed to give rise to any renal structural abnormalities^14,16,17. Elimination of functional pVHL in the kidney proximal tubule epithelial cells increased the number of renal cysts, but only after long latency and with a low penetrance¹⁵. Based on these results, it can be concluded that Vhl is a rather weak tumor suppressor gene in the kidney and that there is a requirement for additional genetic alterations to provoke ccRCC tumor development. In accordance with this theory, researchers have combined kidney specific deletion of Vhl with the deletion of other tumor suppressor genes such as PTEN¹⁶ p53⁵⁹ or Bap1⁶⁰ The two latter, but not the first, do show signs of renal neoplasms. None of these mice however display aggressive tumor growth or epithelial cytoplasmic lipid accumulation, the latter being a cardinal sign of ccRCC^6,7. Cytoplasmic lipid accumulation was however observed in the renal cortex of mice upon constitutive expression of a stabilized form of the HIF-1α, but not HIF-2α^61,62. These data are somewhat surprising considering the observations indicating that HIF-2α rather than HIF-1α is the main tumorigenic driver in the context of VHL deficient tumors. Indeed, tumor suppression by pVHL can be opposed by α overexpression of HIF-2α but not by HIF-1α^11,12.

With regards to the shortcomings of the mouse models based on targeting Vhl it can be speculated that it relates to the selection of the Cre-driver genes, which in previous studies are expressed mainly in other tubular compartments than the proximal tubules alternatively already in the early developing nephron⁶⁰. The proximal tubule specific expression and the fact that the Kap2-iCre is an inducible system makes it superior compared to the previously used proximal tubular specific promoter¹⁵, and would thus give a more disease-relevant model system.

The oncogenic role of aberrant Notch signaling has been established in several tumors including T-cell Acute Lymphoid Leukemia (T-ALL)⁶³, brain tumors²⁹, melanoma²⁸, lung carcinoma²⁶, pancreatic cancer⁶⁴, and epithelial tumors such as breast cancer^65,66,67. In vitro and in vivo data indicate that activation of the Notch pathway contributes to the malignant features of ccRCC^{43,44,45,48,49}. In the present study we used the Kap2 promoter as a driver for an inducible Cre recombinase (Fig. 2A). The expression of the Kap2 promoter has previously been reported to be limited to the proximal tubules of the renal cortex^53,68. This was verified in our study by crossing the Kap2-iCre mouse with the R26R-YFP reporter mouse (Fig. 2B) and further by co-staining of the proximal marker LTA with CaIX as a marker for Vhl loss.

In contrast to previous model systems based on excision of Vhl in the kidney^15,60 we did not note any cyst formation did not occur in our model system. This might be due to the high specificity of the Cre driver to the proximal tubule cells in combination with the pronounced focal expression of the Cre recombinase, as shown by a speckled YFP staining pattern of the proximal tubules in in kidneys of the Kap2-iCre/R26R-YFP mice. In addition, it should be noted that previous model systems relies on constitutive Cre drivers that are expressed also during nephrogenesis. Thus, it remains possible that the timing of the Vhl excision is important for the cystic phenotype. It would therefore be of importance to monitor the Vhl^fl/fl/CALSL-NICD/Kap2-iCre for time periods that exceed 12 months.

Interestingly, despite the lack of cysts we do observed clusters of dysplastic cells with a clear cytoplasm together with distorted tubules and slightly enlarged nuclei. As indicated by ORO staining these cytoplasms shows an excess accumulation of lipids, a feature not noticeable in normal renal epithelium neither in previous Vhl deleted mouse models^14,15,16,17. This phenotype is significantly more pronounced in proximal tubular epithelial cells in the androgen induced Vhl^fl/fl/CALSL-NICD/Kap2-iCre than Vhl^fl/fl/Kap2-iCre mice. Thus, Notch signaling seems to contribute to the cytoplasmic lipid accumulation seen in ccRCC. This notion was further supported by our in vitro studies, showing that lipid accumulation in established ccRCC cells induced with using an adipocyte differentiation protocol display less lipid accumulation upon inhibition of Notch signaling. In accordance with our results, it was recently shown that Notch signaling can induce a lipogenesis and lipid storage in hepatocytes⁶⁹.

In our model system, where we combined deletion of Vhl with ectopic expression of NICD1, we observed several dysplastic nests of cells with a clear cell phenotype, but only one overt neoplasm. It should be kept in mind that the kidney has a low intrinsic cell turn over. Thus, the promising features of our model system might become apparent upon kidney challenge that induce a regenerative process that might convert the dysplastic cells with clear-cell morphology into a full blown ccRCC. This would also allow for further clarification of the role of elevated Notch signaling during the initiation of renal malignancies.

Material and Methods

Generation of transgenic mice

R26R-YFP⁷⁰, Vhl^{fl/fl 52}, CALSL-NICD⁵¹ and Kap2-iCre⁵³ mice strains were purchased from the Jackson Laboratory (Bar Harbor, ME) and were kept under pathogen free conditions. The mice were crossed to generate R26RYFP^tg/+/Kap2-iCre^tg/+, R26RYFP^tg/+, Vhl^fl/fl/CALSL-NICD^tg/+/Kap2-iCre^tg/+, Vhl^fl/fl/Kap2-iCre and Vhl^fl/fl/CALSL-NICD^tg/+; mice and were maintained on a mixed C57BL6/129S background. Various genotypes of the offspring were verified by genotyping. List of primers are provided in Supplemental Table 1. To activate expression/excision of genes, 6–8 week old mice were subjected to testosterone treatment by subcutaneous implantation of a testosterone pellet (10 mg testosterone (Sigma Aldrich, Saint Louis, MO) in beeswax). The mice were followed for up to 12 months post implantation. The mice were euthanized and kidneys were put in RNAlater (Life Technologies, Carlsbad, CA) or formalin for further analysis. All animal procedures were approved by the Malmö-Lund Ethical Committee (Dnr. M64-11 and M12-12) and the use of laboratory animals were conducted in accordance with European Union directive on the subject of animal rights.

Immunostaining

For histological analysis sections of formalin-fixed, paraffin-embedded (FFPE) mouse renal tissue (4 μm) were deparaffinized using xylene followed by graded ethanols for rehydration and stained with hematoxylin and eosin, Periodic-acid schiff (PAS) or Masson’s trichrome according to standard protocol (HistoLab Products AB, Göteborg, Sweden). For IHC boiling in 10 mmol/L citrate buffer at pH 6 was performed as antigen retrieval. Staining was detected using the EnVision system and DAKO Techmate 500 staining equipment according to the instructions of the manufacturer (DAKO, Carpenteria, CA). Paraffin sections were incubated with the following primary antibodies GFP (A290, Abcam, Cambridge, UK), CaIX (AF2344, R&D Systems, Minneapolis, MN), Glut1 (07–1401, Merek Millipore, Darmstadt, Germany), Ki67 (SP6 RM-9601-S, Thermo Scientific, Waltham, MA) and Podocalyxin (AF1556, R&D Systems, Minneapolis, MN). For Oil red O (ORO) stain kidneys were fixed in formalin over night followed by cryo preservation in 30% sucrose over night followed by embedding in optimal cutting temperature compound (O.C.T.) and sectioned (10 μm) on a cryostat.

Lectin and immunoflourescent staining

FFPE mouse renal (4 μm) sections were deparaffinized using xylene followed by graded ethanols for rehydration according to the standard protocol. Antigen retrieval was performed using Diva Decloaker solution (Biocare Medical, Concord, CA). After being blocked with blocking buffer containing 5% BSA in PBS-T, the sections were incubated over night, 4 °C with Lotus tetragonolobus agglutinin (LTA) (FL-1321, Vector laboratories, Burlingame, CA) and CaIX (AF2344, R&D Systems, Minneapolis, MN). After washing, secondary antibody donkey -anti rabbit AlexaFluor-594 (A-11056, Life technologies, Carlsbad, CA) and nuclear stain To-pro-3 iodide (Life technologies, Carlsbad, CA) were applied according to the manufacturer’s instructions followed by rinsing and mounting. Sections were subsequently analyzed by confocal scanning using the Zeiss LSM 710 system (Carl Zeiss AG, Oberkochen, Germany).

Acquisition of human Renal Tissue

Renal tissue for tissue microarray (TMA) was obtained from nephrectomies performed owing to ccRCC malignancy (n = 57) or from renal biopsies (n = 4) performed using 18-gauge needles. All the specimens were collected after informed consent was obtained from the patients. Ethical permission was granted by the ethical committee at Lund University (D282–07) and all experiments were carried out in accordance with the approved guidelines. The TMA was stained with Notch 1 antibody (3E12, Sigma Aldrich Saint Louis, MO).

Real-Time Quantitative PCR

Tissue was collected in RNAlater (Life Technologies, Carlsbad, CA) followed by homogenization using TissueLyser LT (Qiagen, Hilden, Germany). Total RNA was extracted in using RNeasy Mini Kit together with the Qiashredder Kit (Qiagen, Hilden, Germany). An on-column DNAse treatment was included during the extraction. cDNA synthesis was performed using random primers and MultiScribe Reverse Transcriptase enzyme (Applied Biosystems, Foster City, CA). The amplifications were run using 7300 Real-Time PCR (RT-PCR) System (Applied Biosystems, Foster City, CA) with SYBR Green Master Mix (Applied Biosystems, Foster City, CA) and all the detections were performed in triplicate. The housekeeping gene Gapdh was used for normalization. Comparative CT method was used to quantify relative mRNA. The following primer sequences were used: Gapdh forward 5′-TCGTGGATCTGACGTGCCGCC-3′; Gapdh reverse 5′-CACCACCCTGTTGCTGTAGCC-3′; Notch1 forward 5′-CGGGTCCACCAGTTTGAATG-3′; Notch1 reverse 5′-GTTGTATTGGTTCGGCACCAT-3′; Hey1 forward 5′-CTTGAGTTCGGCTCTGTGTTCC-3′′; and Hey1 reverse 5′-GATGCCTCTCCGTCTTTTCCT-3′.

Cell culture and adipocyte differentiation of 786–0 cells

786–0 cells (ATCC, Rockville, MD, USA) were maintained at subconfluence in DMEM High Glucose (GIBCO, Invitrogen, Carlsbad, CA) supplemented with 10% FBS and 1% PEST. Cells were seeded in 6-well plates on coverslips and two-days postconfluent cells were treated 48 h with 0.1 uM dexamethasone (Sigma Aldrich, Saint Louis, MO), 10 ug/ml insulin (Sigma Aldrich Saint, Louis, MO), 100 uM indomethacin (Sigma Aldrich, Saint Louis, MO), 500 uM IBMX (Sigma Aldrich, Saint Louis, MO) and 10 uM DAPT (Sigma Aldrich, Saint Louis, MO) or DMSO followed by 12 days of treatment with 10 ug/ml Insulin (Sigma Aldrich, Saint Louis, MO) and 10 uM DAPT (Sigma Aldrich, Saint Louis, MO) or DMSO with medium change every second day. Coverslips were washed in PBS and fixed in PFA, stained with Oil Red O and counterstained with Mayer’s hematoxylin according to standard procedures, followed by mounting in Faramount aqueous mounting media (DAKO, Carpenteria, CA). Imaging was performed using Olympus BX63 microscope equipped with UPlanSApo objectives (10x/0.40), (20x/0.75), (40x/0.95) and DP80 camera using the CellSens Dimensions imaging software. Images are representative from triplicate experiments.

Bioinformatics analysis

Level 3 RNA-seq data containing mRNA gene-level RSEM estimates were downloaded from The Cancer Genome Atlas (TCGA) data portal (http://tcga-data.nci.nih.gov/tcga/dataAccessMatrix.htm) by September 2014. Gene expression levels for each sample were created by multiplying the gene level RSEM estimate values by 10⁶ followed by adding an offset of 1 and subsequent log2 transformation. The data set comprised 530 primary clear cell renal carcinomas and 70 normal kidney tissue samples.

Statistical analysis

If not otherwise stated, data is presented as mean ± standard deviation. For statistical analysis unpaired t-test was used. P- values: *p < 0.05, **p < 0.01, ***p < 0.001.

Additional Information

How to cite this article: Johansson, E. et al. Simultaneous targeted activation of Notch1 and VHL-disruption in the kidney proximal epithelial tubular cells in mice. Sci. Rep. 6, 30739; doi: 10.1038/srep30739 (2016).

References

Siegel, R., Ward, E., Brawley, O. & Jemal, A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61, 212–236, doi: 10.3322/caac.20121 (2011).
Article PubMed Google Scholar
Amin, M. B. et al. Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. Am J Surg Pathol 26, 281–291 (2002).
Article PubMed Google Scholar
Moch, H. et al. Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma: a Swiss experience with 588 tumors. Cancer 89, 604–614 (2000).
Article CAS PubMed Google Scholar
Davis, C. F. et al. The somatic genomic landscape of chromophobe renal cell carcinoma. Cancer Cell 26, 319–330, doi: 10.1016/j.ccr.2014.07.014 (2014).
Article CAS PubMed PubMed Central Google Scholar
Prasad, S. R. et al. Segmental disorders of the nephron: histopathological and imaging perspective. Br J Radiol 80, 593–602, doi: 10.1259/bjr/20129205 (2007).
Article CAS PubMed Google Scholar
Ericsson, J. L., Seljelid, R. & Orrenius, S. Comparative light and electron microscopic observations of the cytoplasmic matrix in renal carcinomas. Virchows Arch Pathol Anat Physiol Klin Med 341, 204–223 (1966).
Article CAS PubMed Google Scholar
Gebhard, R. L. et al. Abnormal cholesterol metabolism in renal clear cell carcinoma. J Lipid Res 28, 1177–1184 (1987).
CAS PubMed Google Scholar
Kim, W. Y. & Kaelin, W. G. Role of VHL gene mutation in human cancer. J Clin Oncol 22, 4991–5004, doi: 10.1200/JCO.2004.05.061 (2004).
Article CAS PubMed Google Scholar
Banks, R. E. et al. Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer. Cancer Res 66, 2000–2011, doi: 10.1158/0008-5472.can-05-3074 (2006).
Article CAS PubMed Google Scholar
Maxwell, P. H. et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399, 271–275, doi: 10.1038/20459 (1999).
Article ADS CAS PubMed Google Scholar
Kondo, K., Kim, W. Y., Lechpammer, M. & Kaelin, W. G. Jr. Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol 1, E83 (2003).
Article PubMed PubMed Central Google Scholar
Kondo, K., Klco, J., Nakamura, E., Lechpammer, M. & Kaelin, W. G. Jr. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 1, 237–246 (2002).
Article CAS PubMed Google Scholar
Zimmer, M., Doucette, D., Siddiqui, N. & Iliopoulos, O. Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL−/− tumors. Mol Cancer Res 2, 89–95 (2004).
CAS PubMed Google Scholar
Kapitsinou, P. P. & Haase, V. H. The VHL tumor suppressor and HIF: insights from genetic studies in mice. Cell Death Differ 15, 650–659 (2008).
Article CAS PubMed Google Scholar
Rankin, E. B., Tomaszewski, J. E. & Haase, V. H. Renal cyst development in mice with conditional inactivation of the von Hippel-Lindau tumor suppressor. Cancer Res 66, 2576–2583, doi: 10.1158/0008-5472.can-05-3241 (2006).
Article CAS PubMed PubMed Central Google Scholar
Frew, I. J. et al. pVHL and PTEN tumour suppressor proteins cooperatively suppress kidney cyst formation. EMBO J 27, 1747–1757, doi: 10.1038/emboj.2008.96 (2008).
Article CAS PubMed PubMed Central Google Scholar
Shao, X., Somlo, S. & Igarashi, P. Epithelial-specific Cre/lox recombination in the developing kidney and genitourinary tract. J Am Soc Nephrol 13, 1837–1846 (2002).
Article CAS PubMed Google Scholar
Mandriota, S. J. et al. HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. Cancer Cell 1, 459–468 (2002).
Article CAS PubMed Google Scholar
Gerlinger, M. et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat Genet 46, 225–233, doi: 10.1038/ng.2891 (2014).
Article CAS PubMed PubMed Central Google Scholar
Gerlinger, M. et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366, 883–892, doi: 10.1056/NEJMoa1113205 (2012).
Article CAS PubMed PubMed Central Google Scholar
Larkin, J., Goh, X. Y., Vetter, M., Pickering, L. & Swanton, C. Epigenetic regulation in RCC: opportunities for therapeutic intervention? Nat Rev Urol 9, 147–155, doi: 10.1038/nrurol.2011.236 (2012).
Article CAS PubMed Google Scholar
South, A. P., Cho, R. J. & Aster, J. C. The double-edged sword of Notch signaling in cancer. Seminars in Cell & Developmental Biology 23, 458–464, doi: 10.1016/j.semcdb.2012.01.017 (2012).
Article CAS Google Scholar
Ellisen, L. W. et al. TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell 66, 649–661 (1991).
Article CAS PubMed Google Scholar
Dievart, A., Beaulieu, N. & Jolicoeur, P. Involvement of Notch1 in the development of mouse mammary tumors. Oncogene 18, 5973–5981, doi: 10.1038/sj.onc.1202991 (1999).
Article CAS PubMed Google Scholar
Weijzen, S. et al. Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells. Nat Med 8, 979–986, doi: 10.1038/nm754 (2002).
Article CAS PubMed Google Scholar
Chen, Y. et al. Oxygen concentration determines the biological effects of NOTCH-1 signaling in adenocarcinoma of the lung. Cancer Res 67, 7954–7959, doi: 10.1158/0008-5472.can-07-1229 (2007).
Article CAS PubMed Google Scholar
Dang, T. P. et al. Chromosome 19 translocation, overexpression of Notch3, and human lung cancer. J Natl Cancer Inst 92, 1355–1357 (2000).
Article CAS PubMed Google Scholar
Balint, K. et al. Activation of Notch1 signaling is required for beta-catenin-mediated human primary melanoma progression. J Clin Invest 115, 3166–3176, doi: 10.1172/jci25001 (2005).
Article CAS PubMed PubMed Central Google Scholar
Purow, B. W. et al. Expression of Notch-1 and its ligands, Delta-like-1 and Jagged-1, is critical for glioma cell survival and proliferation. Cancer Res 65, 2353–2363, doi: 10.1158/0008-5472.can-04-1890 (2005).
Article CAS PubMed Google Scholar
Bray, S. & Bernard, F. Notch targets and their regulation. Curr Top Dev Biol 92, 253–275, doi: 10.1016/s0070-2153(10)92008-5 (2010).
Article CAS PubMed Google Scholar
Tatarek, J. et al. Notch1 inhibition targets the leukemia-initiating cells in a Tal1/Lmo2 mouse model of T-ALL. Blood 118, 1579–1590, doi: 10.1182/blood-2010-08-300343 (2011).
Article CAS PubMed PubMed Central Google Scholar
Simmons, M. J., Serra, R., Hermance, N. & Kelliher, M. A. NOTCH1 inhibition in vivo results in mammary tumor regression and reduced mammary tumorsphere-forming activity in vitro . Breast Cancer Res 14, R126, doi: 10.1186/bcr3321 (2012).
Article CAS PubMed PubMed Central Google Scholar
Espinoza, I. & Miele, L. Deadly crosstalk: Notch signaling at the intersection of EMT and cancer stem cells. Cancer Lett 341, 41–45, doi: 10.1016/j.canlet.2013.08.027 (2013).
Article CAS PubMed Google Scholar
Wang, J. et al. Notch promotes radioresistance of glioma stem cells. Stem Cells 28, 17–28, doi: 10.1002/stem.261 (2010).
Article CAS PubMed PubMed Central Google Scholar
McAuliffe, S. M. et al. Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy. Proc Natl Acad Sci USA 109, E2939–2948, doi: 10.1073/pnas.1206400109 (2012).
Article PubMed PubMed Central Google Scholar
Meng, R. D. et al. gamma-Secretase inhibitors abrogate oxaliplatin-induced activation of the Notch-1 signaling pathway in colon cancer cells resulting in enhanced chemosensitivity. Cancer Res 69, 573–582, doi: 10.1158/0008-5472.can-08-2088 (2009).
Article CAS PubMed PubMed Central Google Scholar
Landor, S. K. et al. Hypo- and hyperactivated Notch signaling induce a glycolytic switch through distinct mechanisms. Proc Natl Acad Sci USA 108, 18814–18819, doi: 10.1073/pnas.1104943108 (2011).
Article ADS CAS PubMed PubMed Central Google Scholar
Zeng, Q. et al. Crosstalk between tumor and endothelial cells promotes tumor angiogenesis by MAPK activation of Notch signaling. Cancer Cell 8, 13–23, doi: 10.1016/j.ccr.2005.06.004 (2005).
Article CAS PubMed Google Scholar
Noguera-Troise, I. et al. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature 444, 1032–1037, doi: 10.1038/nature05355 (2006).
Article ADS CAS PubMed Google Scholar
Wu, K., Xu, L., Zhang, L., Lin, Z. & Hou, J. High Jagged1 expression predicts poor outcome in clear cell renal cell carcinoma. Jpn J Clin Oncol 41, 411–416, doi: 10.1093/jjco/hyq205 (2011).
Article PubMed Google Scholar
Huang, Q. B. et al. Endothelial Delta-like 4 (DLL4) promotes renal cell carcinoma hematogenous metastasis. Oncotarget 5, 3066–3075 (2014).
PubMed PubMed Central Google Scholar
Wang, W. et al. Delta-like ligand 4: A predictor of poor prognosis in clear cell renal cell carcinoma. Oncol Lett 8, 2627–2633, doi: 10.3892/ol.2014.2554 (2014).
Article ADS PubMed PubMed Central Google Scholar
Sjolund, J. et al. Suppression of renal cell carcinoma growth by inhibition of Notch signaling in vitro and in vivo . J Clin Invest 118, 217–228, doi: 10.1172/jci32086 (2008).
Article PubMed Google Scholar
Sjolund, J. et al. The notch and TGF-beta signaling pathways contribute to the aggressiveness of clear cell renal cell carcinoma. PLoS One 6, e23057, doi: 10.1371/journal.pone.0023057 (2011).
Article ADS CAS PubMed PubMed Central Google Scholar
Ai, Q. et al. High-level expression of Notch1 increased the risk of metastasis in T1 stage clear cell renal cell carcinoma. PLoS One 7, e35022, doi: 10.1371/journal.pone.0035022 (2012).
Article ADS CAS PubMed PubMed Central Google Scholar
Xiao, W., Gao, Z., Duan, Y., Yuan, W. & Ke, Y. Downregulation of miR-19a exhibits inhibitory effects on metastatic renal cell carcinoma by targeting PIK3CA and inactivating Notch signaling in vitro . Oncol Rep 34, 739–746, doi: 10.3892/or.2015.4041 (2015).
Article CAS PubMed Google Scholar
Saad, S., Stanners, S. R., Yong, R., Tang, O. & Pollock, C. A. Notch mediated epithelial to mesenchymal transformation is associated with increased expression of the Snail transcription factor. International Journal of Biochemistry & Cell Biology 42, 1115–1122, doi: 10.1016/j.biocel.2010.03.016 (2010).
Article CAS Google Scholar
Liu, S. et al. NOTCH1 functions as an oncogene by regulating the PTEN/PI3K/AKT pathway in clear cell renal cell carcinoma. Urol Oncol 31, 938–948, doi: 10.1016/j.urolonc.2011.07.006 (2013).
Article CAS PubMed Google Scholar
Liu, S. K. et al. Delta-like ligand 4-notch blockade and tumor radiation response. J Natl Cancer Inst 103, 1778–1798, doi: 10.1093/jnci/djr419 (2011).
Article CAS PubMed Google Scholar
Bostrom, A. K., Lindgren, D., Johansson, M. E. & Axelson, H. Effects of TGF-beta signaling in clear cell renal cell carcinoma cells. Biochemical & Biophysical Research Communications 435, 126–133, doi: 10.1016/j.bbrc.2013.04.054 (2013).
Article CAS Google Scholar
Yang, X. et al. Notch activation induces apoptosis in neural progenitor cells through a p53-dependent pathway. Dev Biol 269, 81–94, doi: 10.1016/j.ydbio.2004.01.014 (2004).
Article CAS PubMed Google Scholar
Haase, V. H., Glickman, J. N., Socolovsky, M. & Jaenisch, R. Vascular tumors in livers with targeted inactivation of the von Hippel-Lindau tumor suppressor. Proc Natl Acad Sci USA 98, 1583–1588, doi: 10.1073/pnas.98.4.1583 (2001).
Article ADS CAS PubMed PubMed Central Google Scholar
Li, H., Zhou, X., Davis, D. R., Xu, D. & Sigmund, C. D. An androgen-inducible proximal tubule-specific Cre recombinase transgenic model. Am J Physiol Renal Physiol 294, F1481–1486, doi: 10.1152/ajprenal.00064.2008 (2008).
Article CAS PubMed Google Scholar
Potter, C. & Harris, A. L. Hypoxia inducible carbonic anhydrase IX, marker of tumour hypoxia, survival pathway and therapy target. Cell Cycle 3, 164–167 (2004).
Article CAS PubMed Google Scholar
Kimura, K. et al. Stable expression of HIF-1alpha in tubular epithelial cells promotes interstitial fibrosis. Am J Physiol Renal Physiol 295, F1023–1029, doi: 10.1152/ajprenal.90209.2008 (2008).
Article CAS PubMed PubMed Central Google Scholar
Ferlay, J. et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127, 2893–2917, doi: 10.1002/ijc.25516 (2010).
Article CAS PubMed Google Scholar
Gnarra, J. R. et al. Defective placental vasculogenesis causes embryonic lethality in VHL-deficient mice. Proc Natl Acad Sci USA 94, 9102–9107 (1997).
Article ADS CAS PubMed PubMed Central Google Scholar
Ma, W. et al. Hepatic vascular tumors, angiectasis in multiple organs, and impaired spermatogenesis in mice with conditional inactivation of the VHL gene. Cancer Res 63, 5320–5328 (2003).
CAS PubMed Google Scholar
Albers, J. et al. Combined mutation of Vhl and Trp53 causes renal cysts and tumours in mice. EMBO Mol Med 5, 949–964, doi: 10.1002/emmm.201202231 (2013).
Article CAS PubMed PubMed Central Google Scholar
Wang, S. S. et al. Bap1 is essential for kidney function and cooperates with Vhl in renal tumorigenesis. Proc Natl Acad Sci USA,doi: 10.1073/pnas.1414789111 (2014).
Fu, L., Wang, G., Shevchuk, M. M., Nanus, D. M. & Gudas, L. J. Generation of a mouse model of Von Hippel-Lindau kidney disease leading to renal cancers by expression of a constitutively active mutant of HIF1alpha. Cancer Res 71, 6848–6856, doi: 10.1158/0008-5472.can-11-1745 (2011).
Article CAS PubMed PubMed Central Google Scholar
Fu, L., Wang, G., Shevchuk, M. M., Nanus, D. M. & Gudas, L. J. Activation of HIF2alpha in kidney proximal tubule cells causes abnormal glycogen deposition but not tumorigenesis. Cancer Res 73, 2916–2925, doi: 10.1158/0008-5472.can-12-3983 (2013).
Article CAS PubMed PubMed Central Google Scholar
Weng, A. P. et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 306, 269–271, doi: 10.1126/science.1102160 (2004).
Article ADS CAS PubMed Google Scholar
Miyamoto, Y. et al. Notch mediates TGF alpha-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell 3, 565–576 (2003).
Article CAS PubMed Google Scholar
Callahan, R. & Egan, S. E. Notch signaling in mammary development and oncogenesis. Journal of Mammary Gland Biology & Neoplasia 9, 145–163, doi: 10.1023/b:jomg.0000037159.63644.81 (2004).
Article Google Scholar
Dickson, B. C. et al. High-level JAG1 mRNA and protein predict poor outcome in breast cancer. Mod Pathol 20, 685–693, doi: 10.1038/modpathol.3800785 (2007).
Article CAS PubMed Google Scholar
Reedijk, M. et al. High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res 65, 8530–8537, doi: 10.1158/0008-5472.can-05-1069 (2005).
Article CAS PubMed Google Scholar
Li, H. et al. Renal proximal tubule angiotensin AT1A receptors regulate blood pressure. American Journal of Physiology: Regulatory, Integrative & Comparative Physiology 301, R1067–1077, doi: 10.1152/ajpregu.00124.2011 (2011).
Article CAS Google Scholar
Pajvani, U. B. et al. Inhibition of Notch uncouples Akt activation from hepatic lipid accumulation by decreasing mTorc1 stability. Nat Med 19, 1054–1060, doi: 10.1038/nm.3259 (2013).
Article CAS PubMed PubMed Central Google Scholar
Srinivas, S. et al. Cre reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus. BMC Dev Biol 1, 4 (2001).
Article CAS PubMed PubMed Central Google Scholar

Download references

Acknowledgements

This research was supported by the Wennergren Foundation Regional ALF Funds, Malmö University Hospital Research Funds, Gunnar Nilsson’s Cancer Foundation, the strategic Cancer Research Program Biocare and the Swedish Cancer Society. This research was supported by the Wennergren Foundation, The Crafoord Foundation, Regional ALF Funds, Malmö University Hospital Research Funds, Gunnar Nilsson’s Cancer Foundation, The strategic Cancer Research Program Biocare and the Swedish Cancer Society.

Author information

Birgitte Rönö
Present address: Present address: Novo Nordisk A/S, Novo Allé, 2880 Bagsvaerd, Denmark.,
Håkan Axelson and Emma M. K. Smith: These authors contributed equally to this work.

Authors and Affiliations

Division of Translational Cancer Research, Department of Laboratory Medicine, Medicon Village, Building 404 A3, Scheelevägen 8, 404A3, Lund, 223 63, Sweden
Elinn Johansson, Birgitte Rönö, David Lindgren, Christina Möller, Håkan Axelson & Emma M. K. Smith
Department of Translational Medicine, Center for Molecular Pathology, Skåne University Hospital, Malmö, 205 02, Sweden
Martin Johansson

Authors

Elinn Johansson
View author publications
You can also search for this author in PubMed Google Scholar
Birgitte Rönö
View author publications
You can also search for this author in PubMed Google Scholar
Martin Johansson
View author publications
You can also search for this author in PubMed Google Scholar
David Lindgren
View author publications
You can also search for this author in PubMed Google Scholar
Christina Möller
View author publications
You can also search for this author in PubMed Google Scholar
Håkan Axelson
View author publications
You can also search for this author in PubMed Google Scholar
Emma M. K. Smith
View author publications
You can also search for this author in PubMed Google Scholar

Contributions

Conception and design E.J., H.A. and E.M.K.S. Acquisition of data E.J., B.R. and C.M. Analysis and interpretation of data: E.J., B.R., E.M.K.S., H.A., M.J., D.L. and C.M. Bioinformatics: D.L. Writing of the manuscript: E.J., H.A., E.M.K.S., M.J. and D.L. All authors review the manuscript.

Corresponding author

Correspondence to Emma M. K. Smith.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary Information (PDF 1577 kb)

Rights and permissions

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

Reprints and permissions

About this article

Cite this article

Johansson, E., Rönö, B., Johansson, M. et al. Simultaneous targeted activation of Notch1 and Vhl-disruption in the kidney proximal epithelial tubular cells in mice. Sci Rep 6, 30739 (2016). https://doi.org/10.1038/srep30739

Download citation

Received: 26 January 2016
Accepted: 07 July 2016
Published: 05 August 2016
DOI: https://doi.org/10.1038/srep30739

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.